Christina Wu, MD
Hematology & Oncology · Scottsdale, AZNPI 1770637191
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Array Biopharma Inc at 26.2% of the total. 2025 is the largest year on record at $5,361, 3.1 times the $1,713 reported in 2021.
Across 21 payments — averaging $887.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Array Biopharma Inc$5K
- Exelixis Inc.$4K
- GSK$3K
- Merck$3K
- Seagen Inc.$2K
- Daiichi Sankyo Inc.$2K
- plus $395 from 5 others
Across 225 payments — averaging $10,971 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$2M
- Amgen$175K
- AbbVie$132K
- Merck$97K
- Seagen Inc.$74K
- Daiichi Sankyo Inc.$23K
What the payments were for
- Consulting fees$8,97348%
- Speaking & faculty fees$8,48145%
- Travel & lodging$3902%
- Food & beverage$7754%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Array Biopharma Inc | 2 | $4,881 |
| Exelixis Inc. | 5 | $3,976 |
| GSK | 1 | $3,200 |
| Merck | 6 | $2,555 |
| Seagen Inc. | 1 | $1,925 |
| Daiichi Sankyo Inc. | 1 | $1,713 |
| Novartis | 1 | $177 |
| AVEO Pharmaceuticals, Inc. | 1 | $161 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Incyte Corporation | 1 | $19 |
| Sobi, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,644 in reported general payments places this provider in the 70th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 20 | $14,196 |
| Ondansetron Hcl | 65 | $581 |
| Prochlorperazine Maleate | 60 | $564 |
| Dexamethasone | 50 | $460 |
| LoperamideLoperamide Hcl | 21 | $192 |
| Oxycodone Hcl | 12 | $163 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 13 | $140 |
| Gabapentin | 11 | $74 |
| Tramadol Hcl | 12 | $54 |
| Furosemide | 13 | $44 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Scottsdale
- Jeffrey SchriberScottsdale$715K
- Tanios Bekaii-SaabScottsdale$527K
- Rajesh KukunoorScottsdale$499K
- Yousef ZakhariaScottsdale$214K
- Thai HoScottsdale$190K
- Alan BryceScottsdale$157K
- Daniel AhnScottsdale$91K
- Brendan CurleyScottsdale$87K
- Alexander StewartScottsdale$76K
- Saurabh ChhabraScottsdale$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.